Investigation of the neuroprotective effects of a novel synthetic compound via the mitochondrial pathway.

The present study aimed to investigate the neuroprotective effect of a novel synthetic compound (5zou) on differentiated PC12 cells against 6‑hydroxydopamine (6‑OHDA) and L‑glutamic acid (L‑Glu) neurotoxin‑induced cell injury and the potential mechanisms involved. 5zou is a 2, 2‑disubstituted 1,2‑dihydropyridine. PC12 cells were treated with 6‑OHDA and L‑Glu to establish neurotoxic cell models. MTT assay, DCFH‑DA staining, Fluo‑4‑AM staining, JC‑1 staining and western blotting were used to determine the changes in cell viability, intracellular reactive oxygen species concentration, Ca2+ influx, mitochondrial membrane potential and the protein expressions of B‑cell lymphoma‑2 (Bcl‑2) and B‑cell lymphoma‑extra large (Bcl‑xL). Morphological analysis demonstrated the effect of 5zous on neuritogenesis and differentiation in PC12 cells. The results suggested that 5zou rescued the cell viability, intracellular ROS level, Ca2+ influx, mitochondrial membrane potential, and expression of Bcl‑2 and Bcl‑xL, which were altered by 6‑OHDA and L‑Glu. The study confirmed that 5zou has neuroprotective effects on neurotoxin‑induced differentiated PC12 cells injury, potentially via the mitochondrial apoptosis pathway.

Introduction

Neurodegenerative diseases are caused by chronic progressive degenerative damage of the central nervous system (1). The number of individuals suffering from neurodegenerative diseases is growing (2). Although the apoptotic cells in brain area have been observed in patients with Parkinson's and/or Alzheimer's disease, the pathogenic mechanism is not clearly established yet (3). Recent studies demonstrate that the regulation of apoptosis has become a target for prevention and treatment in neurodegenerative diseases (4,5).

Various signals are involved in the apoptotic process. As a second messenger, intracellular calcium is required at low level to maintain homeostasis; however, calcium overload produces large amounts of reactive oxygen species (ROS), which interferes with the electron transport chain and reduces the formation of ATP (6). High levels of calcium and ROS promote the opening of mitochondrial permeability transition pores, which leads to mitochondrial membrane potential dissipation (7). Mitochondrial energy dysfunction will lead to apoptosis (8). Anti-apoptotic proteins B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xL) are highly concentrated in the outer membrane of mitochondria and are responsible for mitochondria-mediated apoptosis (9).

SH-SY5Y human neuroblastoma cells and PC12 rat pheochromocytoma cells are common cell models for in vitro investigation of neurodegenerative diseases. PC12 cells have obvious synapses formation, and are capable of producing nerve-related proteins following stimulation by nerve growth factor (NGF) (10). Certain small synthetic molecules have been reported to exhibit neuroprotective activities against neurotoxin-induced toxicity in SH-SY5Y and PC12 cells via mitochondrial pathways (11,12).

The present study examined the neuroprotective effect of a series of 2,2-disubstituted derivatives in differentiated PC12 (DPC12) cells (Table I). Following morphological screening, one synthetic small molecule (5zou) exhibited significant protection against 6-hydroxydopamine (6-OHDA) and L-glutamic acid (L-Glu)-induced cell damage. The molecular mechanisms associated with mitochondria were investigated further.

Table I.

Neuroprotection screening of zou compounds.

Compound	R group	Differentiation status
1	CON(iPr)2	N
2	CONEt2	N
3	CON(OMe)Me	N
4	CON(CH2)5	N
5	CON(CH2)4O	Y
6	CO2Me	N
7	CN	N

Differentiation status was determined by morphological analysis. PC12 cells were treated with each compound (40 µM) for 24 h and subsequently imaged using an inverted microscope.

Materials and methods

Synthesis of compound 5zou

Under an N2 atmosphere at 30°C were added 1,4-diazabicyclo [2.2.2] octane (20 mol%), compound 1 (as presented in Fig. 1; 1 mmol, 291 mg), MBH carbonate (1.2 mmol, 276 mg) and CH3CN (10 ml) to a dried 10 ml reaction tube. The reaction was monitored by thin layer chromatography (TLC). Upon completion, the reaction mixture was concentrated in vacuo. The crude mixture was purified by column chromatography [silica gel, EtOAc/petroleum ether (60–90°C)] to provide compound 3 (299 mg, 77% yield). mp: 78.5–79.2°C; 1H NMR (300 MHz, CDCl3) δ 7.23 (d, J=0.9 Hz, 1H), 6.36 (d, J=0.9 Hz, 1H), 6.13 (dd, J=9.8, 0.9 Hz, 1H), 5.72 (s, 1H), 5.43 (dd, J=9.8, 0.8 Hz, 1H), 4.41 (q, J=7.1 Hz, 2H), 3.72 (s, 3H), 3.70–3.65 (m, 4H), 3.61 (d, J=13.9 Hz, 1H), 3.55–3.50 (m, 4H), 2.83 (d, J=13.8 Hz, 1H), 1.41 (t, J=7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 167.08, 166.92, 152.20, 132.95, 131.96, 130.26, 122.82, 118.35, 117.42, 109.65, 66.90, 64.55, 57.37, 52.42, 45.61, 40.33, 14.33. HRMS (ESI): calcd. for C19H24N3O6 ([M+H]+): 390.1660, found 390.1650 (13).

Figure 1.

Procedure for novel zou (compound 3) preparation.

Cell culture

PC12 rat adrenal cells (obtained from the American Type Culture Collection, Manassas, VA, USA; CRL-1721; passages <10) were cultured in in Dulbecco's modified Eagle medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) which was supplemented with 5% horse serum (Invitrogen; Thermo Fisher Scientific, Inc.), 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.), penicillin (100 U/ml), and streptomycin (100 µg/ml) (Invitrogen; Thermo Fisher Scientific, Inc.), under a humidified atmosphere containing 5% CO2 at 37°C. The culture medium was changed every three days. PC12 cells were differentiated for 48 h using 50 ng/ml of NGF (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) dissolved in DMEM medium containing 1% FBS, 1% horse serum and 100 U/ml penicillin/streptomycin.

Cellular morphology analysis

PC12 cells were seeded in 6-well plates at 2×104 cells/well. After replacing the medium with serum-free basic medium, cells were treated with 40 µM of the synthetic compounds detailed in Table I, and 10, 20 and 40 µM 5zou for 24 h and then imaged using an inverted microscope (x10; Nikon Corporation, Tokyo, Japan). Cells with projections and a longer neurite (neurite length range, 5–37 µm), compared with untreated undifferentiated cells (neurite length range, 2–15 µm), were considered as differentiated.

Cell viability analysis

DPC12 cells were seeded in 96-well plates at 2×104 cells/well, and pretreated with 5zou (10–40 µM) for 3 h, and then exposed to 100 µM 6-OHDA and 25 mM L-Glu for another 24 h. After incubation with MTT solution (0.5 mg/ml) for 4 h at 37°C in darkness, 100 µl dimethyl sulfoxide was added to dissolve crystals. A microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to measure the absorbance at 540 nm. Viability values were expressed as a percentage of that of corresponding control cells.

Hoechst staining analysis

Nuclear morphological alterations were analyzed by Hoechst 33342 staining. DPC12 cells were pre-treated with 20 and 40 mM 5zou for 3 h, followed with 24 h co-incubation with 100 µM 6-OHDA and 25 mM L-Glu. Then cells were incubated with Hoechst 33342 (5 µg/ml; Sigma-Aldrich; Merck KGaA) for 15 min at 37°C in darkness. After washing with PBS, the fluorescence intensity in the nucleus was captured using a fluorescent microscope (x20; Axio Observer Z1; Carl Zeiss AG, Oberkochen, Germany). The percentage of damaged cells was analyzed by measuring the blue fluorescence intensity using Image J 1.38x software (National Institutes of Health, Bethesda, MA USA).

Intracellular calcium concentration ([Ca2+]i) analysis

DPC12 cells were seeded in a 6-well plate (2×105 cells/well). The next day, cells were treated with 20 and 40 µM 5zou for 3 h prior to co-incubation with 100 µM 6-OHDA and 25 mM L-Glu for 12 h. Then, the supernatant was removed, and cells were incubated with 5 µM Fluo-4-AM (Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min at 37°C in darkness. After three washes, cells were observed using a fluorescence microscope (x20; Axio Observer Z1). The average of green fluorescence intensity was detected using Image J software and expressed as a percentage of that of the corresponding control cells.

Mitochondrial membrane potential (MMP) analysis

DPC12 cells (1×105 cells/well) were seeded into a 6-well plate. Cells were pre-treated with 20 and 40 µM 5zou for 3 h, followed with 12 h co-incubation with 100 µM 6-OHDA and 25 mM L-Glu. Treated cells were incubated with 2 µM 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzimidazolylcarbocyanine iodide (JC-1) (Sigma-Aldrich; Merck KGaA) at 37°C for 10 min. Fluorescent microscope (x20; CCD camera, Axio Observer Z1; Carl Zeiss, Germany) was applied to record the fluorescent color in each group. The ratio of red to green fluorescence intensity was detected by Image J software and expressed as a percentage of that of corresponding control cells.

Measurement of ROS

Intracellular ROS levels were analyzed using a ROS assay kit obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). DPC12 cells were exposed to 20 and 40 µM 5zou for 3 h, and co-incubated with 6-OHDA (100 µM) and L-Glu (25 mM) for 12 h. Treated cells were incubated with 10 µM dichlorofluorescein diacetate (DCFH-DA) at 37°C for 30 min. The fluorescent color was photographed by a fluorescent microscope (x20Axio Observer Z1). The average green fluorescence intensity was detected by Image J and expressed as a percentage of that of corresponding control cells.

Western blot

DPC12 cells were pre-treated with 20 and 40 µM 5zou for 3 h, and followed with 24-h incubation of 6-OHDA (100 µM) and L-Glu (25 mM). Cells were lysed by radioimmunoprecipitation assay buffer (Sigma-Aldrich; Merck KGaA) containing 2% phenylmethanesulfonyl fluoride (Sigma-Aldrich; Merck KGaA) and 1% protease inhibitor cocktail (Sigma-Aldrich; Merck KGaA). Protein concentrations were determined using a Standard BCA Protein Assay kit (Merck KGaA). Proteins (30 µg) were separated on a 12% SDS-PAGE gel and electrophoretically transferred onto nitrocellulose membranes (Bio Basic, Inc., Markham, ON, Canada). The membranes were blocked in 5% bovine serum albumin at room temperature for 4 h, and then incubated with the following primary antibodies (all diluted 1:1,000) overnight at 4°C: Bcl-2 (ab321224), Bcl-xL (ab7973), and GAPDH (ab8245) (1:1,000; Abcam, Cambridge, UK) at 4°C overnight, followed by incubation with appropriate horseradish peroxidase-conjugated secondary antibodies (sc-2005 and sc-358925) at dilution of 1:2,000 at 4°C for 4 h (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Chemiluminescence was detected by using enhanced chemiluminescence detection kits (GE Healthcare Life Sciences, Little Chalfont, UK).

Statistical analysis

All data are presented as the mean ± standard deviation. Data were evaluated by one-way analysis of variance to detect statistical significance, followed by post-hoc multiple comparisons (Dunn's test) using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

5zou increases DPC12 cells differentiation

PC12 cells in the control group, treated with basic DMEM, were round, short spindle and triangular, and their nuclei were large and round. Cells became a polygonal shaped following 5zou treatment. With the increasing 5zou concentration, cell differentiation rate was increased (Fig. 2).

Figure 2.

5zou induced PC12 cell differentiation. Scale bar, 50 µm.

5zou protected neurotoxin-induced DPC12 cell damage

6-OHDA and L-Glu resulted in a 60.8 and 57.2% reduction in cell viability, respectively (P<0.001; Fig. 3), which was partially restored following 5zou pre-treatment (P<0.05; Fig. 3).

Figure 3.

5zou increases the cell viability in differentiated PC12 cells exposed to 6-OHDA or L-Glu for 24 h. Data are expressed as the mean ± standard deviation (n=6). ###P<0.001 vs. CTRL; *P<0.05, **P<0.01 and ***P<0.001 vs. L-Glu-treated or 6-OHDA-treated cells. CTRL, control; 6-OHDA, 6-hydroxydopamine; L-Glu, L-glutamic acid.

Hoechst 33342 staining demonstrated that the nuclei in control cells exhibit a uniform weak light blue fluorescence. However, in 6-OHDA and L-Glu-treated DPC12 cells, most cells were asymmetrical and appeared chunky in shape with intense blue fluorescence. Pretreatment with 5zou for 3 h pretreatment strongly reversed the nuclear damage in DPC12 cells (P<0.05; Fig. 4).

Figure 4.

5zou restored 6-OHDA or L-Glu-induced nucleus morphological alterations detected by Hoechst 33342 staining. Scale bar, 100 µm. Numerical data demonstrate the average blue fluorescence intensity. Data are expressed as the mean ± standard deviation (n=3). ###P<0.001 vs. CTRL; *P<0.05 and ***P<0.001 vs. L-Glu-exposed or 6-OHDA-exposed cells. CTRL, control; 6-OHDA, 6-hydroxydopamine; L-Glu, L-glutamic acid.

Effects of 5zou on intracellular Ca2+ concentration, ROS levels and mitochondrial function

6-OHDA and L-Glu increased the levels of intracellular Ca2+ in DPC12 cells after 12 h incubation (Fig. 5). Compared with model cells, 5zou reduced intracellular Ca2+ concentration, indicated by reduced green fluorescence (P<0.05; Fig. 5).

Figure 5.

Intracellular Ca2+ overload induced by 6-OHDA or L-Glu is rescued by 5zou. Cells were stained with Fluo-4-AM. Scale bar, 100 µm. Numerical data demonstrate the average fluorescence intensity. Data are expressed as the mean ± standard deviation (n=3). #P<0.05 and ###P<0.001 vs. CTRL; *P<0.05 and **P<0.01 vs. L-Glu-treated or 6-OHDA-treated cells. CTRL, control; 6-OHDA, 6-hydroxydopamine; L-Glu, L-glutamic acid.

DCFH-DA is oxidized to produce a highly fluorescent substance when oxidized, and is this used as a probe for measuring the levels of ROS. High green fluorescence was clearly observed in DPC12 cells treated with 6-OHDA and L-Glu, which was significantly reduced in 5zou-treated cells, suggesting 5zou successfully inhibited ROS accumulation (P<0.05; Fig. 6).

Figure 6.

5zou reduces accumulation of reactive oxygen species induced by 6-OHDA or L-Glu in differentiated PC12 cells. Cells were stained with dichlorofluorescein diacetate. Scale bar, 100 µm (n=3). Numerical data demonstrate by the average green fluorescence density. Data are expressed as the mean ± standard deviation (n=3). ###P<0.001 vs. CTRL; ***P<0.001 vs. L-Glu-treated or 6-OHDA-treated cells. CTRL, control; 6-OHDA, 6-hydroxydopamine; L-Glu, L-glutamic acid.

JC-1 staining is widely used as an indicator of the MMP, producing red florescence in normal cells and green fluorescence in unhealthy cells. In L-Glu and 6-OHDA treated cells, weak red fluorescence and strong green fluorescence were observed (P<0.001; Fig. 7). 5zou alleviated MMP dissipation in neurotoxin-induced DPC12 cells, indicated by the enhancement of red fluorescence (P<0.001; Fig. 7).

Figure 7.

5zou rescues the mitochondrial membrane potential disruption induced by by 6-OHDA or L-Glu. Scale bar, 100 µm. Cells were stained with JC-1. Numerical data present the ratio of red to green fluorescence intensity. Data are expressed as the mean ± standard deviation (n=3). ###P<0.001 vs. CTRL; ***P<0.001 vs. L-Glu-exposed or 6-OHDA-treated cells. CTRL, control; 6-OHDA, 6-hydroxydopamine; L-Glu, L-glutamic acid.

Effects of 5zou on Bcl-2 and Bcl-xL expression in DPC12 cells

Compared with the control group, the protein expressions levels of Bcl-xL and Bcl-2 protein were decreased in PC12 cells treated with 6-OHDA and L-Glu compared with control cells (Fig. 8). Pretreatment with 5zou, especially at 20 µM, increased the levels of Bcl-2 and Bcl-xL compared with 6-OHDA and L-Glu treatments. However, 40 µM 5zou failed to reverse the low expression levels of Bcl-xL and Bcl-2 in 6-OHDA-treated cells (Fig. 8).

Figure 8.

5zou enhances Bcl-2 and Bcl-xL expressions in differentiated PC12 cells exposed to 6-OHDA and L-Glu for 24 h. Ctrl, control; 6-OHDA, 6-hydroxydopamine; L-Glu, L-glutamic acid; Bcl-2, B-cell lymphoma-2; Bcl-xL, B-cell lymphoma-extra large.

Discussion

As the most important excitatory neurotransmitter in the central nervous system, glutamic acid has important roles in the formation of synapses. However, markedly increased glutamate levels, caused by physical or chemical factors, leads to excitatory neurotoxicity (14). 6-OHDA, a catecholamine hydroxylated derivative, is commonly used as a selective catecholaminergic nerve agent (15). In the present study, 6-OHDA and L-Glu were used to induce PC12 cell damage, and the protective effect of 5zou on cell apoptosis and the associated molecular mechanisms were subsequently examined.

In the present study, 5zou was been demonstrated to have a significant protective effect on 6-OHDA and L-Glu-induced cell viability reduction, Ca2+ overload, ROS accumulation and MMP dissipation. Mitochondria are the main organelle involved in cell energy metabolism. Intracellular Ca2+ overload is one of the main causes of mitochondrial dysfunction (16). Mitochondrial permeability is associated with cell toxicity, oxidative damage and apoptosis. The leakage from the mitochondrial respiratory chain produces superoxide radicals, then causes ROS generation, which will ultimately lead to intracellular oxidative stress (17). ROS accumulation may further induce mitochondrial damage, which affects the respiratory chain and the inner and outer mitochondrial membrane proteins, resulting in cytochrome C release, and triggering of the mitochondrial apoptosis pathway (18). The imbalance of intracellular ROS homeostasis is considered to be responsible for cell oxidative damage (19). The data of the present study demonstrated that 5zou exhibited strong protective effects against neurotoxin-induced DPC12 cell damage associated with ROS-dependent mitochondrial apoptosis.

Previous studies have demonstrated that the balance of Bcl-2 family members regulates mitochondrial function. 6-OHDA and L-Glu induce mitochondrial dysfunction by regulating the Bcl-2/Bax ratio in SH-SY5Y or PC12 cells, thus contributing to cell apoptosis (20,21). Bcl-2 suppresses apoptosis via two distinct pathways. The BH1-3 domains of Bcl-2 form a hydrophobic pocket, binding and inhibiting pro-apoptotic proteins, and additionally, inositol 1,4,5-trisphosphate receptors prevent Ca2+ influx-induced apoptosis (22). 5zou was demonstrated to improve the neurotoxin-induced MMP dissipation, and also inhibit the abnormal changes to Bcl-2 and Bcl-xL expressions. Thus, 5zou affects the mitochondrial apoptosis pathway to inhibit 6-OHDA and L-Glu-induced cell damage.

A high concentration of L-Glu was used in the present study. For in vitro experiments, 20–25 mM of L-Glu has been previously used to induce damage of DPC12 cells (23,24). In previous experiments performed by our group, 25 mM L-Glu was used to establish neurotoxic DPC12 cell models (25). In the present study, fluorescence intensity measurements were normalized by cell counting of stained and unstained cells, which is a potential limitation; future studies will involve counterstaining, to further improve the accuracy of the results.

Notably, the results indicated that the same concentration of 5zou exhibited different effects on 6-OHDA and L-Glu damaged PC12 cells, which may be related to different injuries on the neurons, occurring via different signaling pathways. In conclusion, the present study demonstrated the neuroprotective effect of a novel compound (5zou). The effect of 5zou may be associated with the mitochondrial apoptotic pathway.